SCHEMBL3592599

SCHEMBL3592599

CC(C)N(CCOc1ccc(Nc2ncc(-c3ccsc3)s2)c(C(F)(F)F)c1)C(C)C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
LIMK1 P53667 2/20 0.34
ADORA2A P29274 2/20 0.33
ADORA1 P30542 2/20 0.33
LIMK2 P53671 1/20 0.33
LTA4H P09960 1/20 0.33
ACHE P22303 2/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
P2RY1 P47900 1/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDR P35968 1/20 0.31
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606184 0.92 FLT1 (0.36) LIMK1LIMK2P2RY1KDR
SCHEMBL3610222 0.90 LMNA (0.36) LIMK1ESR1KDR
SCHEMBL5706315 0.89 FLT1 (0.41) LIMK1KDR
SCHEMBL3593802 0.85 LIMK1 (0.43) LIMK1LIMK2P2RY1KDRPDGFRB
SCHEMBL3597476 0.82 IGF1R (0.43) MCHR1LTA4HESR1ESR2KDR
SCHEMBL3595740 0.81 MCHR1 (0.42) MCHR1CHRNB2CHRNA4LTA4HACHE
SCHEMBL3597088 0.78 TNIK (0.41) ESR1ESR2P2RY1KDR
SCHEMBL3609701 0.78 PIK3CA (0.41) MCHR1KDRPDGFRBPDGFRA
SCHEMBL3605827 0.72 KDR (0.43) LTA4HESR1KDR
SCHEMBL3611617 0.70 CDK4 (0.45) MCHR1ESR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP claimed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US claimed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US claimed
EP-1687285-B1 THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-05 EP disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-7795288-B2 Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors NOVARTIS PHARMA AG (CH) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167449-A1 Thiazole and pyrazole derivatives as flt-3 kinase inhibitors FLT3, FLT1, FLT4 MCHR1 4449/4885CHRNB2 4673/4885CHRNA4 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.